City of Hope Comprehensive Cancer Center

Beckman Research Institute

Duarte, CA

Accepting patients

SEA-CD70

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
Learn more
  • Monoclonal Antibody
  • Phase 1

Not yet accepting

NEXI-001

Phase 1b Expansion Study of Multi-Antigen Specific CD8+ T Cells After Decitabine-enhanced Lymphodepletion: an Adoptive Cellular Therapy for Patients with Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation from Matched HLA Donors
Learn more
  • Allogeneic Stem Cell Transplant
  • T Cell (Allogeneic)
  • Post-Allogeneic Stem Cell Transplant
  • Phase 1
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

ACCESS

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)
Learn more
  • Allogeneic Stem Cell Transplant
  • Pre-Transplant
  • Phase 2

Not currently accepting

A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Leukemias or Myelodysplastic Syndrome (MDS)
Learn more
  • Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
  • Phase 1/2

Accepting patients

Total Marrow and Lymphoid Irradiation

Phase II Study of Evaluating the Efficacy of Total Marrow and Lymphoid Irradiation (TMLI) as the Conditioning Regimen for HLA-Haploidentical Hematopoietic Cell Transplantation in Patients With Myelodysplasia or Acute Leukemia
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

Basiliximab

Phase I Study of Escalating Doses of 90Y-DOTA-Anti-CD25 Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan, and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome
Learn more
  • Chemotherapy
  • Monoclonal Antibody
  • CD25
  • Radiation
  • Phase 1

Accepting patients

Pembrolizumab, Decitabine +/- Venetoclax

Phase 1b Study of Pembrolizumab, Decitabine +/- Venetoclax Combination Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Monoclonal Antibody
  • Phase 1

Accepting patients

BTX-A51

A First-In-Human, Open-Label, Escalating Multiple-Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX-A51 Capsules Alone and in Combination With Azacitidine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Learn more
  • CK1-Alpha Inhibitor
  • Phase 1
  • Has results

Accepting patients

Total Marrow and Lymphoid Irradiation

Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) Combined With Fludarabine and Melphalan as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome
Learn more
  • Chemotherapy
  • Radiation
  • Phase 1

Accepting patients

SL-401

Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 1